Vendor, Mahwah, NJ, part of Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Inc., USA
UEI PVN7LJM7LEY7, CAGE 7A4E3
2 awards and $0 obligated between February 9, 2024 and July 28, 2026, 100% under full and open competition, against 500.5 offers on average where reported.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 36E79720D0068February 9, 2024, Full and Open Competition, 2 offers | Nac PharmaceuticalsDepartment of Veterans Affairs | Cost Recovery Fee and Submission of Quarterly Sales Report Changes Effective 2/9/2024 for Aprepitant Capsules with Glenmark Pharmaceuticals,NAICS 325412, PSC 6505 | $0 |
| 36F79723D0012March 14, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | FSSNAICS 325412, PSC 6505 | $0 |
- Product and service codes
- 6505 Drugs and Biologicals
- Transactions
- 22 across 2 awards